Columbia Partners L L C Investment Management raised its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 7.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,242 shares of the medical equipment provider’s stock after purchasing an additional 878 shares during the quarter. Columbia Partners L L C Investment Management’s holdings in Zimmer Biomet Holdings were worth $1,550,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. BlackRock Inc. boosted its holdings in shares of Zimmer Biomet Holdings by 4.1% in the 2nd quarter. BlackRock Inc. now owns 17,419,463 shares of the medical equipment provider’s stock valued at $2,236,657,000 after purchasing an additional 679,080 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Zimmer Biomet Holdings by 2.6% in the 2nd quarter. Vanguard Group Inc. now owns 13,380,517 shares of the medical equipment provider’s stock valued at $1,718,057,000 after purchasing an additional 339,106 shares during the last quarter. Longview Partners Guernsey LTD boosted its holdings in shares of Zimmer Biomet Holdings by 17.7% in the 3rd quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock valued at $878,958,000 after purchasing an additional 1,128,973 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Zimmer Biomet Holdings by 8.1% in the 3rd quarter. American Century Companies Inc. now owns 4,165,353 shares of the medical equipment provider’s stock valued at $487,721,000 after purchasing an additional 311,654 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Zimmer Biomet Holdings by 20.2% in the 2nd quarter. Northern Trust Corp now owns 4,010,274 shares of the medical equipment provider’s stock valued at $514,919,000 after purchasing an additional 673,079 shares during the last quarter. Institutional investors own 85.44% of the company’s stock.

Zimmer Biomet Holdings, Inc. (ZBH) traded down $0.63 on Friday, hitting $111.61. 1,031,586 shares of the stock traded hands, compared to its average volume of 1,364,669. The company has a market cap of $22,730.00, a P/E ratio of 13.90, a P/E/G ratio of 1.74 and a beta of 1.17. Zimmer Biomet Holdings, Inc. has a one year low of $98.20 and a one year high of $133.49. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.47 and a quick ratio of 0.78.

Zimmer Biomet Holdings (NYSE:ZBH) last released its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.74 by ($0.02). The company had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.83 billion. Zimmer Biomet Holdings had a return on equity of 16.29% and a net margin of 8.36%. Zimmer Biomet Holdings’s revenue for the quarter was down .8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.79 EPS. sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.03 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Zimmer Biomet Holdings, Inc. (ZBH) Shares Bought by Columbia Partners L L C Investment Management” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://theolympiareport.com/2017/11/18/zimmer-biomet-holdings-inc-zbh-shares-bought-by-columbia-partners-l-l-c-investment-management.html.

Several equities analysts recently weighed in on ZBH shares. BidaskClub lowered shares of Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Cantor Fitzgerald set a $137.00 target price on shares of Zimmer Biomet Holdings and gave the company a “hold” rating in a report on Thursday, July 27th. Canaccord Genuity lowered shares of Zimmer Biomet Holdings from a “buy” rating to a “hold” rating and reduced their target price for the company from $141.00 to $135.00 in a report on Friday, July 28th. Piper Jaffray Companies restated a “buy” rating and set a $135.00 target price on shares of Zimmer Biomet Holdings in a report on Friday, July 28th. Finally, Oppenheimer Holdings, Inc. set a $137.00 target price on shares of Zimmer Biomet Holdings and gave the company a “buy” rating in a report on Friday, July 28th. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $133.71.

Zimmer Biomet Holdings Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.